BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$1.15 USD
-0.02 (-1.71%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioXcel Therapeutics, Inc. [BTAI]
Reports for Purchase
Showing records 81 - 100 ( 110 total )
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Leveraging the Digital Age; BXCL501 Program Initiative With Wearable Digital Devices; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Department of Defense Grant Award Underscores BXCL501 Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; BXCL501 Pivotal Program Starting Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Phase 1b Data Highly Favorable, Setting the Stage for Rapid Progress Into Pivotal Testing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Regulatory Milestones Achieved; Pipeline Progressing Rapidly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; R-D Day Event Showcases BXCL501 Development Scope; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Thin Film Formulation Process Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive AVP-786 Pivotal Data Draws Attention to BXCL501 in Alzheimer''s Disease-Related Agitation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Anticipating Further Clinical Progress in 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Established Pharma Firms Join the Party; Triplet Regimen Slated for Assessment in Pancreatic Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Further Proof-of-Concept Data in Opioid Withdrawal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Proof-of-Concept Achieved in Alzheimer''s Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Investigational New Drug Application Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Proof-of-Concept Established; Healthy Cash Runway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Poster Presentation at Upcoming Medical Meeting Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BXCL501 Slated to Advance Into Clinical Testing Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First BXCL701 Investigational New Drug Filing Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Immuno-Oncology Partnership Expanded Into Clinical Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Translational Medicine, Clinical Pharmacology and Regulatory Affairs Head Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Head of Global Pharmaceutical Development and Operations Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R